Bicyclic Hydroxy-1H-pyrrolopyridine-trione Containing HIV-1 Integrase Inhibitors

Chemical Biology and Drug Design

Volumn 79, Issue 2, 2012, Pages 157-165

  Zhao, Xue Zhi ^a   Maddali, Kasthuraiah ^a   Metifiot, Mathieu ^a   Smith, Steven J ^a   Vu, B Christie ^a   Marchand, Christophe ^a   Hughes, Stephen H ^a   Pommier, Yves ^a   Burke, Terrence R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Drug discovery; Mechanism based drug design; Nonpeptide

Indexed keywords

2 (3 CHLORO 4 FLUOROBENZYL) 7 HYDROXY 4 (HYDROXYMETHYL) 1H PYRROLO[3,4 C]PYRIDINE 1,3,6(2H,5H)TRIONE; 2 (3 CHLORO 4 FLUOROBENZYL) 7 HYDROXY 4 ISOBUTYL 5 ISOPROPYL 1H PYRROLO[3,4 C]PYRIDINE 1,3,6(2H,5H)TRIONE; 2 (3 CHLORO 4 FLUOROBENZYL) 7 HYDROXY 4 METHYL 5 PHENYL 1H PYRROLO[3,4 C]PYRIDINE 1,3,6(2H,5H)TRIONE; 2 (3 CHLORO 4 FLUOROBENZYL) 7 HYDROXY 4,5 DIMETHYL 1H PYRROLO[3,4 C]PYRIDINE 1,3,6(2H,5H)TRIONE; 4,5 DIHYDROXY 1H ISOINDOLE 1,3(2H)DIONE; [2 (3 CHLORO 4 FLUOROBENZYL) 7 HYDROXY 1,3,6 TRIOXO 2,3,5,6 TETRAHYDRO 1H PYRROLO[3,4 C]PYRIDIN 4 YL]METHYL ACETATE; [2 (3 CHLORO 4 FLUOROBENZYL) 7 HYDROXY 5 ISOPROPYL 1,3,6 TRIOXO 2,3,5,6 TETRAHYDRO 1H PYRROLO[3,4 C]PYRIDIN 4 YL]METHYL ACETATE; BICYCLIC HYDROXY 1H PYRROLOPYRIDINE TRIONE; INTEGRASE INHIBITOR; METHYL 3 [2 (3 CHLORO 4 FLUOROBENZYL) 7 HYDROXY 5 ISOPROPYL 1,3,6 TRIOXO 2,3,5,6 TETRAHYDRO 1H PYRROLO[3,4 C]PYRIDIN 4 YL]PROPANOATE; MK 0536; RALTEGRAVIR; UNCLASSIFIED DRUG;

ACYLATION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; CYCLIZATION; CYCLOADDITION; DEPROTONATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; PRIORITY JOURNAL; PUMMERER REACTION; VIRUS MUTANT; WILD TYPE;

AMINO ACID SUBSTITUTION; BICYCLO COMPOUNDS; BINDING SITES; CELL LINE, TUMOR; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; IMIDES; MUTATION; PYRIDINES; PYRIDONES; PYRROLIDINONES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84855422942     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01270.x     Document Type: Article

References (26)

1. Pommier Y., Johnson A.A., Marchand C. (2005) Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov;4:236-248.
2. Pommier Y., Cherfils J. (2005) Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends Pharmacol Sci;26:138-145.
3. Anker M., Corales R.B. (2008) Raltegravir (mk-0518): a novel integrase inhibitor for the treatment of HIV infection. Expert Opin Investig Drugs;17:97-103.
4. Summa V., Petrocchi A., Bonelli F., Crescenzi B., Donghi M., Ferrara M., Fiore F. et al. (2008) Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem;51:5843-5855.
5. De Clercq E. (2009) Anti-HIV drugs: 25 compounds approved within 25years after the discovery of HIV. Int J Antimicrob Agents;33:307-320.
6. Marchand C., Maddali K., Metifiot M., Pommier Y. (2009) HIV-1 in inhibitors: 2010 update and perspectives. Curr Top Med Chem;9:1016-1037.
7. Johns B.A., Svolto A.C. (2008) Advances in two-metal chelation inhibitors of HIV integrase. Expert Opin Ther Pat;18:1225-1237.
8. Hare S., Gupta S.S., Valkov E., Engelman A., Cherepanov P. (2010) Retroviral intasome assembly and inhibition of DNA strand transfer. Nature;464:232-236.
9. Cherepanov P., Maertens G.N., Hare S. (2011) Structural insights into the retroviral DNA integration apparatus. Curr Opin Struct Biol;21:249-256.
10. Marinello J., Marchand C., Mott B.T., Bain A., Thomas C.J., Pommier Y. (2008) Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry;47:9345-9354.
11. Fransen S., Gupta S., Danovich R., Hazuda D., Miller M., Witmer M., Petropoulos C.J., Huang W. (2009) Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol;83:11440-11446.
12. Muraglia E., Kinzel O., Gardelli C., Crescenzi B., Donghi M., Ferrara M., Nizi E. et al. (2008) Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors. J Med Chem;51:861-874.
13. Metifiot M., Marchand C., Maddali K., Pommier Y. (2010) Resistance to integrase inhibitors. Viruses;2:1347-1366.
14. Metifiot M., Vandegraaff N., Maddali K., Naumova A., Zhang X., Rhodes D., Marchand C., Pommier Y. (2011) Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS;25:1175-1178.
15. Zhao X.Z., Semenova E.A., Vu B.C., Maddali K., Marchand C., Hughes S.H., Pommier Y., Burke T.R. Jr (2008) 2, 3-dihydro-6, 7-dihydroxy-1I-isoindol-1-one-based HIV-1 integrase inhibitors. J Med Chem;51:251-259.
16. Zhao X.Z., Maddali K., Vu B.C., Marchand C., Hughes Stephen H., Pommier Y., Burke Terrence R. Jr (2009) Examination of halogen substituent effects on HIV-1 integrase inhibitors derived from 2, 3-dihydro-6, 7-dihydroxy-1H-isoindol-1-ones and 4, 5-dihydroxy-1H-isoindole-1, 3(2H)-diones. Bioorg Med Chem Lett;19:2714-2717.
17. Zhao X.Z., Maddali K., Metifiot M., Smith S.J., Christie Vu B., Marchand C., Hughes S.H., Pommier Y., Burke T.R. (2011) Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors. Bioorg Med Chem Lett;21:2986-2990.
18. Padwa A., Heidelbaugh T.M., Kuethe J.T. (1999) Synthesis of substituted 2-pyridones via the Pummerer cyclization' deprotonation' cycloaddition cascade of imidosulfoxides. J Org Chem;64:2038-2049.
19. Miah S., Slawin A.M.Z., Moody C.J., Sheehan S.M., Marino J.P. Jr, Semones M.A., Padwa A., Richards I.C. (1996) Ligand effects in the rhodium(II) catalyzed reactions of diazoamides and diazoimides. Tetrahedron;52:2489-2514.
20. Zouhiri F., Mouscadet J.-F., Mekouar K., Desmaele D., Savourr D., Leh H., Subra F., Le Bret M., Auclair C., d'Angelo J. (2000) Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. J Med Chem;43:1533-1540.
21. Padwa A., Heidelbaugh T.M., Kuethe J.T. (2000) Using the Pummerer cyclization' deprotonation' cycloaddition cascade of imidosulfoxides for alkaloid synthesis. J Org Chem;65:2368-2378.
22. Croxtall J.D., Scott L.J. (2010) Raltegravir: in treatment-naive patients with HIV-1 infection. Drugs;70:631-642.
23. Hare S., Vos A.M., Clayton R.F., Thuring J.W., Cummings M.D., Cherepanov P. (2010) Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci USA;107:20057-20062.
24. Cherepanov P. (2010) Integrase illuminated. EMBO Rep;11:328.
25. Perryman A.L., Forli S., Morris G.M., Burt C., Cheng Y., Palmer M.J., Whitby K., McCammon J.A., Phillips C., Olson A.J. (2010) A dynamic model of HIV integrase inhibition and drug resistance. J Mol Biol;397:600-615.
26. Grobler J.A., Stillmock K.A., Miller M.D., Hazuda D.J. (2008) Mechanism by which the HIV integrase active-site mutation N155H confers resistance to raltegravir. Antivir Ther;13:A41.